© 1998 by Oxford University Press
Journal Of The National Cancer Institute, Vol 90, 1205-1211, Copyright © 1998 by Oxford University Press
DR Budman, DA Berry, CT Cirrincione, IC Henderson, WC Wood, RB Weiss, CR Ferree, HB Muss, MR Green, L Norton and E Frei 3rd
BACKGROUND: Both total dose and dose intensity of adjuvant chemotherapy are
postulated to be important variables in the outcome for patients with
operable breast cancer. The Cancer and Leukemia Group B study 8541 examined
the effects of adjuvant treatment using conventional-range dose and dose
intensity in female patients with stage II (axillary lymph node-positive)
breast cancer. METHODS: Within 6 weeks of surgery (radical mastectomy,
modified radical mastectomy, or lumpectomy), 1550 patients with unilateral
breast cancer were randomly assigned to one of three treatment arms: high-,
moderate-, or low-dose intensity. The patients received cyclophosphamide,
doxorubicin, and 5-fluorouracil on day 1 of each chemotherapy cycle, with
5-fluorouracil administration repeated on day 8. The high-dose arm had
twice the dose intensity and twice the drug dose as the low-dose arm. The
moderate-dose arm had two thirds the dose intensity as the high-dose arm
but the same total drug dose. Disease-free survival and overall survival
were primary end points of the study. RESULTS: At a median follow-up of 9
years, disease- free survival and overall survival for patients on the
moderate- and high-dose arms are superior to the corresponding survival
measures for patients on the low-dose arm (two-sided P<.0001 and
two-sided P = .004, respectively), with no difference in disease-free or
overall survival between the moderate- and the high-dose arms. At 5 years,
overall survival (average +/- standard error) is 79% +/- 2% for patients on
the high-dose arm, 77% +/- 2% for the patients on the moderate-dose arm,
and 72% +/- 2% for patients on the low-dose arm; disease-free survival is
66% +/- 2%, 61% +/- 2%, and 56% +/- 2%, respectively. CONCLUSION: Within
the conventional dose range for this chemotherapy regimen, a higher dose is
associated with better disease-free survival and overall survival.
ARTICLES
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B
Department of Medicine, North Shore University Hospital-New York University School of Medicine, Manhasset 11030, USA. budman@nshs.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Gianni, L. Norton, N. Wolmark, T. M. Suter, G. Bonadonna, and G. N. Hortobagyi Role of Anthracyclines in the Treatment of Early Breast Cancer J. Clin. Oncol., October 1, 2009; 27(28): 4798 - 4808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Harris, G. Broadwater, M. Abu-Khalaf, D. Cowan, A. D. Thor, D. Budman, C. T. Cirrincione, D. A. Berry, E. P. Winer, C. A. Hudis, et al. Topoisomerase II{alpha} Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013 J. Clin. Oncol., July 20, 2009; 27(21): 3430 - 3436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Muss, D. A. Berry, C. T. Cirrincione, M. Theodoulou, A. M. Mauer, A. B. Kornblith, A. H. Partridge, L. G. Dressler, H. J. Cohen, H. P. Becker, et al. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer N. Engl. J. Med., May 14, 2009; 360(20): 2055 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Hershman, J. M. Unger, W. E. Barlow, L. F. Hutchins, S. Martino, C. K. Osborne, R. B. Livingston, and K. S. Albain Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897 J. Clin. Oncol., May 1, 2009; 27(13): 2157 - 2162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. de Azambuja, M. Paesmans, M. Beauduin, A. Vindevoghel, N. Cornez, C. Finet, F. Ries, M. T. Closon-Dejardin, J. Kerger, P. Gobert, et al. Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study J. Clin. Oncol., February 10, 2009; 27(5): 720 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jenkins and S. Freeman Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer Ann. Onc., January 1, 2009; 20(1): 34 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Morris, H. L. McArthur, C. T. Dang, and C. A. Hudis Selection of Appropriate Patients for Anthracycline Therapy ASCO Educational Book, January 1, 2009; 2009(1): 11 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo Advances in Breast Cancer: Pathways to Personalized Medicine Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. DiGiovanna, D. F. Stern, S. Edgerton, G. Broadwater, L. G. Dressler, D. R. Budman, I. C. Henderson, L. Norton, E. T. Liu, H. B. Muss, et al. Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B J. Clin. Oncol., May 10, 2008; 26(14): 2364 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Field, S. Kosmider, M. Jefford, M. Michael, R. Jennens, M. Green, and P. Gibbs Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide Survey J. Oncol. Pract, May 1, 2008; 4(3): 108 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Lyman Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern J. Oncol. Pract, May 1, 2008; 4(3): 114 - 115. [Full Text] [PDF]
|
|
|
|
|
|
G. Fountzilas, U. Dafni, H. Gogas, H. Linardou, H. P. Kalofonos, E. Briasoulis, D. Pectasides, E. Samantas, D. Bafaloukos, G. P. Stathopoulos, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 Ann. Onc., May 1, 2008; 19(5): 853 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. F. Moore Ovarian Failure after Chemotherapy for Breast Cancer and the Role of Gonadotropin-releasing Hormone Analogs in Protection of Ovarian Function ASCO Educational Book, January 1, 2008; 2008(1): 39 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Balducci, H. Al-Halawani, V. Charu, J. Tam, S. Shahin, L. Dreiling, and W. B. Ershler Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim Oncologist, December 1, 2007; 12(12): 1416 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hayes, A. D. Thor, L. G. Dressler, D. Weaver, S. Edgerton, D. Cowan, G. Broadwater, L. J. Goldstein, S. Martino, J. N. Ingle, et al. HER2 and Response to Paclitaxel in Node-Positive Breast Cancer N. Engl. J. Med., October 11, 2007; 357(15): 1496 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Courneya, R. J. Segal, J. R. Mackey, K. Gelmon, R. D. Reid, C. M. Friedenreich, A. B. Ladha, C. Proulx, J. K.H. Vallance, K. Lane, et al. Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial J. Clin. Oncol., October 1, 2007; 25(28): 4396 - 4404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Findlay, K. Tonkin, M. Crump, B. Norris, M. Trudeau, M. Blackstein, M. Burnell, J. Skillings, D. Bowman, D. Walde, et al. A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes Ann. Onc., October 1, 2007; 18(10): 1646 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Muss, D. A. Berry, C. Cirrincione, D. R. Budman, I. C. Henderson, M. L. Citron, L. Norton, E. P. Winer, and C. A. Hudis Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience J. Clin. Oncol., August 20, 2007; 25(24): 3699 - 3704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Blijlevens and S Sonis Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis Ann. Onc., May 1, 2007; 18(5): 817 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Walshe, N. Denduluri, and S. M. Swain Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer J. Clin. Oncol., December 20, 2006; 24(36): 5769 - 5779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lohrisch, C. Paltiel, K. Gelmon, C. Speers, S. Taylor, J. Barnett, and I. A. Olivotto Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2006; 24(30): 4888 - 4894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Neugut, M. Matasar, X. Wang, R. McBride, J. S. Jacobson, W.-Y. Tsai, V. R. Grann, and D. L. Hershman Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly J. Clin. Oncol., May 20, 2006; 24(15): 2368 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Monk, G. Phillips, R. Waite, J. Kuhn, L. J. Schaaf, G. A. Otterson, D. Guttridge, C. Rhoades, M. Shah, T. Criswell, et al. Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients J. Clin. Oncol., April 20, 2006; 24(12): 1852 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman, L. J. Goldstein, S. Martino, E. A. Perez, H. B. Muss, L. Norton, et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer JAMA, April 12, 2006; 295(14): 1658 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist, February 1, 2006; 11(2): 111 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gluck Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin Oncologist, November 1, 2005; 10(10): 780 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hershman, R. McBride, J. S. Jacobson, L. Lamerato, K. Roberts, V. R. Grann, and A. I. Neugut Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6639 - 6646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. A. Ioannidis Contradicted and Initially Stronger Effects in Highly Cited Clinical Research JAMA, July 13, 2005; 294(2): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Dressler, D. A. Berry, G. Broadwater, D. Cowan, K. Cox, S. Griffin, A. Miller, J. Tse, D. Novotny, D. L. Persons, et al. Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients J. Clin. Oncol., July 1, 2005; 23(19): 4287 - 4297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Howell and A. M Wardley Overview of the impact of conventional systemic therapies on breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S9 - S16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Griggs, M. E. S. Sorbero, and G. H. Lyman Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy Arch Intern Med, June 13, 2005; 165(11): 1267 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Lyman, C. H. Lyman, O. Agboola, and for the Anc Study Group Risk Models for Predicting Chemotherapy-Induced Neutropenia Oncologist, June 1, 2005; 10(6): 427 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. P. Peters, G. L. Rosner, J. J. Vredenburgh, E. J. Shpall, M. Crump, P. G. Richardson, M. W. Schuster, L. B. Marks, C. Cirrincione, L. Norton, et al. Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13 J. Clin. Oncol., April 1, 2005; 23(10): 2191 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Panades, I. A. Olivotto, C. H. Speers, T. Shenkier, T. A. Olivotto, L. Weir, S. J. Allan, and P. T. Truong Evolving Treatment Strategies for Inflammatory Breast Cancer: A Population-Based Survival Analysis J. Clin. Oncol., March 20, 2005; 23(9): 1941 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Muss, S. Woolf, D. Berry, C. Cirrincione, R. B. Weiss, D. Budman, W. C. Wood, I. C. Henderson, C. Hudis, E. Winer, et al. Adjuvant Chemotherapy in Older and Younger Women With Lymph Node-Positive Breast Cancer JAMA, March 2, 2005; 293(9): 1073 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Dang, G. M. D'Andrea, M. E. Moynahan, M. N. Dickler, A. D. Seidman, M. Fornier, M. E. Robson, M. Theodoulou, D. Lake, V. E. Currie, et al. Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer Clin. Cancer Res., September 1, 2004; 10(17): 5754 - 5761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Lyman, D. C. Dale, and J. Crawford Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices J. Clin. Oncol., December 15, 2003; 21(24): 4524 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hershman, M. Weinberg, Z. Rosner, K. Alexis, A. Tiersten, V. R. Grann, A. Troxel, and A. I. Neugut Ethnic Neutropenia and Treatment Delay in African American Women Undergoing Chemotherapy for Early-Stage Breast Cancer J Natl Cancer Inst, October 15, 2003; 95(20): 1545 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bernard-Marty, M. Mano, M. Paesmans, C. Accettura, R. Munoz-Bermeo, T. Richard, K. Kleiber, F. Cardoso, J. P. Lobelle, D. Larsimont, et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients Ann. Onc., May 1, 2003; 14(5): 693 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Citron, D. A. Berry, C. Cirrincione, C. Hudis, E. P. Winer, W. J. Gradishar, N. E. Davidson, S. Martino, R. Livingston, J. N. Ingle, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J. Clin. Oncol., April 15, 2003; 21(8): 1431 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Henderson, D. A. Berry, G. D. Demetri, C. T. Cirrincione, L. J. Goldstein, S. Martino, J. N. Ingle, M. R. Cooper, D. F. Hayes, K. H. Tkaczuk, et al. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer J. Clin. Oncol., March 15, 2003; 21(6): 976 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot, A. Bremond, M. Namer, S. Schraub, M.-J. Goudier, J. Mihura, A. Monnier, et al. Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial J. Clin. Oncol., January 15, 2003; 21(2): 298 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Morrow, M. Siegel, S. Boone, G. Lawless, and W. Carter Chemotherapy Dose Intensity Determination as a Quality of Care Measure for Managed Care Organizations in the Treatment of Early-Stage Breast Cancer American Journal of Medical Quality, November 1, 2002; 17(6): 218 - 224. [Abstract] [PDF]
|
|
|
|
|
|
A. J. Guidi, D. A. Berry, G. Broadwater, B. Helmchen, I. J. Bleiweiss, D. R. Budman, I. C. Henderson, L. Norton, and D. F. Hayes Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869 J. Clin. Oncol., February 1, 2002; 20(3): 732 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Fornier, A. D. Seidman, M. Theodoulou, M. E. Moynahan, V. Currie, M. Moasser, N. Sklarin, T. Gilewski, G. D'Andrea, R. Salvaggio, et al. Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide versus Concurrent Paclitaxel and Cyclophosphamide: 5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma Clin. Cancer Res., December 1, 2001; 7(12): 3934 - 3941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Kostler, M. Hejna, C. Wenzel, and C. C. Zielinski Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment CA Cancer J Clin, September 1, 2001; 51(5): 290 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Piccart, A. Di Leo, M. Beauduin, A. Vindevoghel, J. Michel, C. Focan, A. Tagnon, F. Ries, P. Gobert, C. Finet, et al. Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer J. Clin. Oncol., June 15, 2001; 19(12): 3103 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial J. Clin. Oncol., February 1, 2001; 19(3): 602 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Berry, H. B. Muss, A. D. Thor, L. Dressler, E. T. Liu, G. Broadwater, D. R. Budman, I. C. Henderson, M. Barcos, D. Hayes, et al. HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor-Positive, Node-Positive Breast Cancer J. Clin. Oncol., October 20, 2000; 18(20): 3471 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Thor, S. Liu, S. Edgerton, D. Moore II, K. M. Kasowitz, C. C. Benz, D. F. Stern, and M. P. DiGiovanna Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation With Outcome in Breast Cancer J. Clin. Oncol., September 15, 2000; 18(18): 3230 - 3239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fisher, S. Anderson, A. DeCillis, N. Dimitrov, J. N. Atkins, L. Fehrenbacher, P. H. Henry, E. H. Romond, K. S. Lanier, E. Davila, et al. Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-25 J. Clin. Oncol., November 1, 1999; 17(11): 3374 - 3388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R Adams and T. L Brenner Oprelvekin (Neumega(R)) Journal of Oncology Pharmacy Practice, September 1, 1999; 5(3): 117 - 124. [Abstract] [PDF]
|
|
|
|
|
|
W. Hryniuk Re: Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer J Natl Cancer Inst, August 18, 1999; 91(16): 1425 - 1425. [Full Text] [PDF]
|
|
|
|
|
|
Y. Nieto, P. J. Cagnoni, E. J. Shpall, S. Matthes, A. Baron, R. B. Jones, and S. I. Bearman Phase II Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplant for Stage IV Breast Cancer with Minimal Metastatic Disease Clin. Cancer Res., July 1, 1999; 5(7): 1731 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jakesz, H. Hausmaninger, K. Haider, E. Kubista, H. Samonigg, M. Gnant, D. Manfreda, G. Tschurtschenthaler, R. Kolb, M. Stierer, et al. Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node-Positive Breast Cancer J. Clin. Oncol., June 1, 1999; 17(6): 1701 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Berry and A. D. Thor RESPONSE: Re: erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer J Natl Cancer Inst, April 21, 1999; 91(8): 728a - 729a. [Full Text] [PDF]
|
|
|
|
|
|
C. Kouroussis, N. Androulakis, S. Kakolyris, J. Souglakos, T. Kotsakis, D. Mavroudis, K. Katsogridakis, N. Vardakis, D. Hatzidaki, G. Samonis, et al. Dose-Escalation Study of Docetaxel in Combination With Mitoxantrone as First-Line Treatment in Patients With Metastatic Breast Cancer J. Clin. Oncol., March 1, 1999; 17(3): 862 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Vollmer, D. A. Berry, and D. R. Budman Re: Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer • Response J Natl Cancer Inst, February 3, 1999; 91(3): 286aa - 287aa. [Full Text] [PDF]
|
|